Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs
Phase of Trial: Phase IV
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Canagliflozin; Empagliflozin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms CVD-REAL
- Sponsors AstraZeneca
- 05 Oct 2018 Results assessing the outcomes across larger number of countries and patients, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 20 Sep 2018 According to an AstraZeneca media release, data from this trial will be presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) (Oct 2018).
- 25 Jun 2018 Results presented in an AstraZeneca media release.